Clinical effect of telbivudine in pregnant patients with e antigen-negative chronic hepatitis B

Abstract

Objective To investigate clinical effect of telbivudine used in e antigen-negative chronic hepatitis B pregnant patients, to provide a reference for clinical treatment. Methods 90 pregnant patients with chronic hepatitis B e antigen-negative were selected, they were divided into two groups, 50 patients in the control group and 40 patients in the observation group.The observation group used telbivudine treatment, the control group used the compound glycyrrhizin treatment.Before and after treatment, HBV DNA levels, negative rate, serum ALT levels, pregnancy outcome were compared between the two groups. Results After treatment, HBV-DNA in the two groups was significantly decreased compared with before treatment, before treatment, the HBV-DNA of the control group was (6.37±1.18)mL, 6 weeks after delivery was (5.49±1.21)mL; before treatment, the HBV-DNA of the observation group was (6.31±1.21)mL, 6 weeks after delivery was (0.23±0.04)mL.The difference was statistically significant (t=8.154, P<0.01). In the observation group, before birth, six weeks after childbirth HBV-DNA were (0.21±0.05)lg copy/mL, (0.23±0.04)lg copy/mL, which were significantly lower than those of the control group, the differences were significant (t=19.257, P=0.000; t=8.154, P=0.000).4 weeks, 8 weeks after treatment, six weeks after childbirth, the HBV-DNA negative conversion rates of the control group were 52.00%, 60.00%, 88.00%, which were significantly lower than the observation group (χ2=177.61, 142.41, 184.58, P<0.01). Compared with before treatment, ALT levels after treatment were significantly decreased in the two groups (t=29.665, P<0.01). Before birth, six weeks after birth, ALT levels in the observation group were (12.58±2.58)U/L, (18.44±3.43)U/L, which were significantly lower than the control group (t=54.251, P=0.000; t=29.665, P=0.000). The incidence rate of adverse pregnancy of the observation group was 14.00%, compared with the control group the difference was not statistically significant (χ2=0.524, P=0.493). Conclusion Telbivudine in the treatment of gestational e antigen-negative chronic hepatitis B pregnant patients has good clinical effect, it can help to control hepatitis activity and reduce virus levels, which is worthy of clinical application. Key words: Hepatitis B, chronic; Telbivudine; Pregnancy; E antigen